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Expression of the mucosal yl T cell receptor V region repertoire in
patients with IgA nephropathy. IgA nephropathy (IgAN) is characterized
by the deposition of IgA in the glomerular mesangium and often leads to
progressive renal dysfunction and kidney failure. We have previously
shown that the mesangial IgA is likely to derive from the bone marrow
plasma cells, and suggested that a primary abnormality within the mucosal
immune system may underly the pathogenesis of IgAN. This study has
analyzed the T cell receptor (TCR) variable (V) region expression by yfi
T cells in the intestinal mucosa of patients with IgAN. The Vy and V
usage of TCR transcripts was determined using a semiquantitative reverse
transcriptase-PCR protocol. Primers specific for the four human Vy and
six V subfamilies were used each with a constant (C) y or C specific
primer, and the PCR-amplifled TCR transcripts were detected by South-
ern blotting and oligonucleotide hybridization. yfi TCR V region expres-
sion was determined in gut biopsies and peripheral blood of 11 patients
with IgAN, and the TCR Vy and V repertoires were compared to those
in gut and peripheral blood of Ii control individuals. yfi T cells in normal
blood predominantly expressed Vy2 (Vy9 gene) and V2 gene segments
whereas those in normal gut mainly expressed Vy3 and V3. In IgAN
patients, V2 was also the predominant V gene utilized by peripheral
blood y T cells, however, we observed a predominance of Vy3 and
reduced Vy2 usage by these cells. yfi T cells in the gut of IgAN patients
mainly used Vy3 and VM. While the y and TCR V region repertoires
did not differ significantly between the peripheral blood of patients and
controls, there were significant differences in Vy and Vfi repertoire
expression between IgAN and control gut biopsies. Vy3 gene expression
was significantly decreased in IgAN gut compared to control gut (P =
0.023). In addition, there was a significant decrease in Vfi3 gene expression
in IgAN gut compared to control gut (P 0.043). These findings indicate
that a subpopulation of y T cells, which represent the majority of y T
cells in normal gut mucosa, are significantly diminished in the gut of
patients with IgAN. This suggests that a "hole" in the mucosal y T cell
repertoire may play a fundamental role in contributing to the pathogenesis
of IgAN.
IgA nephropathy (IgAN) is one of the most common forms of
glomerulonephritis worldwide and often leads to end-stage renal
failure [1, 2]. The diagnostic hallmark of IgAN is deposition of
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IgA in the glomerular mesangium [3, 4], but the site of synthesis
of this IgA, the reasons for its deposition within the mesangium,
and the pathogenetic mechanisms leading to glomerular damage
remain unclear.
It is generally accepted that the underlying abnormality in IgAN
is within the IgA immune system rather than the kidney. IgA
deposits reappear in about half of normal kidneys transplanted
into recipients with IgAN [5], and, conversely, there have been
reports of the disappearance of IgA from kidneys of IgAN donors
inadvertently transplanted into non-IgAN recipients [6, 7]. Mes-
angial IgA in IgAN is known to be of the IgAl subclass, and to be
polymeric, containing J-chain [81. Polymeric IgA (pIgA) is nor-
mally produced in large quantities at mucosal surfaces, from
where it is transported across the epithelium into mucosal secre-
tions, forming part of the primary defence against potential
pathogens. Very little of this pIgA reaches the circulation; serum
IgA is mostly monomeric and is derived from the bone marrow. In
IgAN, circulating levels of IgAl polymer are raised [8], particu-
larly in response to immunization [9, 10]. These observations,
along with the association of clinical disease exacerbations with
mucosal infection [11], have led to the assumption that mesangial
IgA is derived from the mucosal IgA system in IgAN. However,
we have demonstrated that pIgA production in the duodenal
lamina propria is strikingly down-regulated in IgAN [12], while it
is up-regulated in the bone marrow [13—16]. These findings
suggest that the bone marrow is the likely source of mesangial IgA
in IgAN, but that the increased bone marrow production may be
secondary to a fundamental flaw in mucosal IgA immunity. Since
IgA production is T cell dependent, we investigated the possibility
that the failure of pIgA production in the duodenal lamina
propria in IgAN is secondary to a defect at this site of a specific T
cell subset, namely y8 T cells.
The physiological role of y6 T cells is unclear. While y8 T cells
share many features of af3 T cells including helper and cytotoxic
effector functions, and cytokine production [17], there are funda-
mental differences between these two cell types, particularly with
respect to antigen recognition. Unlike a T cells, which require
MHC molecules for antigen presentation, yfi T cells rarely see
antigen in an MHC-restricted manner [17]. In addition, mycobac-
terial heat shock proteins appear to be preferentially recognized
by y T cells [18, 19], although a number of other bacterial ligands
that stimulate yfi T cells have been identified [20—22]. These
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Table 1. Clinical details of 11 subjects with IgA nephropathy
IgA, 1gM
IgA only
IgA, C3
IgA, C3
IgA, C3
TgA only
IgA only
IgA only
IgA, C3
IgA only
IgA, C3
No
No
Yes
Yes
No
No
No
Yes
No
No
No
negative
negative
negative
negative
negative
negative
+++
negative
++
negative
negative
Proteinuria was not quantified at the time of study; but in both patients with stick-positive proteinuria serum albumin was normal.
include low molecular weight non-peptidic compounds [20], and
phosphorylated molecules representing naturally occurring prod-
ucts of bacterial metabolism [21, 22]. y T cells represent a minor
population of circulating peripheral blood T cells [23] but have an
increased frequency among intra-epithelial lymphocytes (TEL)
within the gut mucosa of both the small intestine [24] and colon
[25]. Therefore, it is likely that IEL contribute to host defence
against environmental antigens that have gained access to the
mucosal system. It has been suggested that mucosal immunity may
be impaired in patients with IgAN, which allows antigens to access
the circulation leading to systemic IgA production and the
deposition of IgA in the glomerular mesangium [8]. In view of
this, we have examined IgAN patients for a potential defect in
their mucosal yfi T cell repertoire.
y T cells express a T cell receptor (TCR) composed of a y and
1 TCR chain [231. The TCR chains are comprised of individual
variable (V), diversity, joining, and constant (C) region gene
segments that undergo rearrangement during T cell ontogeny to
produce functionally rearranged TCR V region genes [23]. In
comparison to af3 T cells there are considerably fewer Vy and V
genes. In humans, there are eight functional Vy genes in four Vy
subfamilies [23]. The V-yl subfamily contains five of these Vy
gene segments (Vy2, 3, 4, 5 and 8) whereas subfamilies Vy2, Vy3
and Vy4 each contain a single V gene segment; Vy9, VylO and
Vyll, respectively [23]. Six V6 genes have been identified [231.
To determine the diversity of y T cell populations in IgAN,
this study has analyzed the V region repertoire of yfi TCR in the
intestinal mucosa and peripheral blood of patients with IgAN and
compared this to they TCR V region repertoire in gut and blood
of controls. y TCR V region expression was determined using a
semiquantitative reverse transcriptase-PCR employing primers
specific for the four human Vy and six V subfamilies, each with
a C-y or C specific primer. PCR-amplified TCR transcripts were
detected by Southern blotting and oligonucleotide hybridization.
The data suggest that a "hole" in the mucosal y5 T cell repertoire
may play a fundamental role in contributing to the pathogenesis of
IgAN.
METHODS
Patients and controls
Eleven patients (10 male, mean age 46,4 years, range 26 to 60
years) with renal biopsy-proven IgAN were examined. Clinical
details of the patients are shown in Table 1. Patients had no
symptoms suggestive of gastrointestinal disease and no mucosal
infection or macroscopic hematuria at the time of study; none
were nephrotic. None of the patients had ever been treated with
corticosteroids or immunosuppressive drugs. Mean serum creati-
nine was 108 xmol/liter (range 65 to 250 imol/liter). Only one
patient had serum creatinine raised above the reference range;
this patient subsequently developed progressive renal failure.
Eleven age- and sex-matched controls (9 male, mean age 43.5
years, range 22 to 74 years) were examined. Controls were
individuals undergoing upper gastrointestinal tract evaluation in
whom gastric and duodenal mucosae appeared macroscopically
normal and in which subsequent microscopic examination was
also normal. No gastrointestinal pathology was identified in any of
the controls. Patients and controls were not receiving agents
known to interfere with mucosal function.
Peripheral blood and gut biopsies
Peripheral blood was collected from all individuals at the time
when gut biopsies were taken. PBMC were separated following
density gradient centrifugation over Ficoll (Pharmacia, North
Ryde, NSW, Australia). Endoscopic biopsies from the second part
of the duodenum were obtained from patients and controls.
Endoscopies were performed entirely as part of the research
protocol for this study which had approval from the appropriate
ethics committee.
RNA extraction and eDNA synthesis
RNA was extracted from PBMC and gut biopsies using a
single-step guanidinium thiocyanate/phenol chloroform proce-
dure according to Chomczynski and Sacchi [26]. RNA yield was
estimated by spectrophotometry and denaturing agarose gel dcc-
trophoresis after staining with ethidium bromide and comparison
with known standards. Approximately 2 p.g total RNA was
converted to eDNA by incubation for one hour at 37°C in a 50 1.d
reaction containing 50 mM Tris/HC1 (pH 8.3), 75 mivi KC1, 3 mM
MgCI2, 10 mvi dithiothreitol, 1 ifiM of each dNTP, 500 ng oligo dT,
25 units RNAsin (Promega, Sydney, Australia) and 50 units
M-MuLV reverse transcriptasc (Pharmacia). Reactions were pu-
rified by phenol/chloroform extraction.
Disease Past history of Serum
duration Immune macroscopic Proteinuria creatinine°
Gender Age years Light microscopy deposits hematuria (urine stick test) pmol/liter Drugs
M 53 7 minimal change
M 36 10 minimal change
M 26 3 diffuse mesangial hypercellularity
M 49 14 diffuse mesangial hypercellularity
M 53 4 minimal change
M 42 1 segmental hypercellularity
M 60 13 mesangial matrix expansion
M 34 24 segmental hypercellularity
M 51 8 segmental hypercellularity
F 50 8 minimal change
M 57 8 mesangial matrix
92 none
95 none
75 none
80 anti-hypertensives
97 none
94 none
250 anti-hypertensives
124 anti-hypertensives
110 anti-hypertensivcs
65 none
100 none
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Semiquantitation of PCR
Twofold serial dilutions of a known concentration of pooled
PBMC cDNA obtained from four normal healthy individuals were
used for the construction of GAPDH and TCR C6 PCR standard
curves, as previously described [271. Briefly, PCR amplification
was carried out in triplicate for each dilution of eDNA using the
forward 5'-ACCACAGTCCATGCCATCAC-3' and reverse 5'-
TCCACCACCCTGTTGCTGTA-3' GAPDH primers, and the
forward CMV 5'-TcAGCCTCATACCAAACCATC-3' and re-
verse CM 5 '-GACAGCAYT'GTACTflTCCCACTGG-3' TCR C6
primers, respectively. PCR conditions for both GAPDH and TCR
C6 were one minute each at 95°C, 60°C and 72°C for 30 cycles.
The specificity of each PCR product (5 jd) was confirmed by
Southern blotting and hybridization with internal GAPDH (5'-
GATGACATCAAGAAGGTGGTG-3') and TCR CMI (5'-
TTCACCAGACAAGCGACA-3') oligonucleotide probes that
were end-labeled with y32P-ATP. Two dimensional densitometry
was undertaken on the autoradiographs using a computerized
densitometer (Molecular Dynamics) and ImageQuant V 3.0 soft-
ware. Following densitometry, PCR standard curves were con-
structed over a range of eDNA concentrations.
Standardization of PBMC and gut cDNA samples
An aliquot of each eDNA sample was used for PCR amplifica-
tion of GAPDH and TCR C6 using the same conditions as those
used for construction of the PCR standard curves. PCR products
were Southern blotted and hybridized with internal GAPDH and
TCR C6 oligonucleotide probes, respectively. Following densi-
tometry on each hybridizing DNA band, the concentration of each
cDNA sample was estimated by extrapolation from the PCR
standard curves. eDNA samples were diluted accordingly and the
PCR amplification was repeated to ensure that amplification
remained within the limits of the standard curves.
PCR amplification of TCR Cl and TCR Ca transcripts
The TCR C6 primers, CMV and CM, were used for PCR
amplification of TCR C6 transcripts in the cDNA samples.
PCR-amplified TCR C8 transcripts were identified by hybridiza-
tion with the CMI probe. For PCR amplification of TCR Ca
transcripts in the cDNA samples the forward 5'-AATATCCA-
GAACCCTGACCCT-3' and reverse 5-GCTCCAGGCCACAG-
CACTGTTGCT-3' TCR Ca primers were used with the same
conditions as those used for TCR 6 chain amplification. PCR-
amplified TCR Ca transcripts were detected by hybridization with
an internal Ca probe (5'-CAGAC1TGTCACTGGA-3').
PCR amplification of TCR Vy and V chain transcripts
cDNA samples standardised for TCR C6 gene expression were
subjected to V region specific PCR amplification of rearranged
TCR V-C transcripts. Each 50 d PCR reaction contained 10 mivi
Tris/HCI (pH 8.4), 50 ms KCI, 1.5 mM MgCl2, 0.01% (wt/vol)
gelatin, 0.2 m'vi of each dNTP, 25 pmole each of forward (V
region) and reverse (C region) primer, and 1.25 units Taq DNA
polymerase (Promega). Primers for the four TCR Vy and six V6
subfamilies, and those for Cy and C6 have previously been
published [28]. Pooled normal PBMC eDNA was used as a
positive control for PCR amplification. Negative PCR controls
contained all the reaction components for PCR except for eDNA
template. PCR conditions for amplification of PBMC and gut
eDNA samples were identical. Amplification of TCR Vy and V6
transcripts was carried out for one minute each at 95°C, 50°C and
72°C for 35 cycles, or 40 cycles for amplification involving Vy4,
V64 and V66. PCR products (5 fL!) were electrophoresed in a
1.25% agarose gel and the length of the products assessed by
comparison with molecular size standards after staining with
ethidium bromide. The specificity of each PCR product was
confirmed by Southern blotting and hybridization with internal
TCR Cy (5'-GGAAACATCTGCATCAAGTFGT-3') and TCR
CMII (5'-GATGGTTTGGTATGAGGCTGA-3') probes that
were end-labeled with y12P-ATP.
Southern blotting and oligonucleotide hybridization
PCR products (5 fxl) were transferred to a nylon membrane
(Amersham, Castle Hill, NSW, Australia) by Southern blotting.
Oligonucleotides directed at segments internal to the amplified
TCR C6, TCR Ca, GAPDH, TCR Vy and TCR V6 transcripts
were end-labeled with y32P-ATP by incubation for 45 minutes at
37°C in a 20 jxl reaction containing 50 mi Tris/HC1 (pH 7.5), 20
mM MgCI2, 20 mivi dithiothreitol, 40 jtCi [-y-32P]ATP (Bresatec,
Adelaide, SA, Australia) and 10 units T4 polynucleotide kinase
(Pharmacia). Hybridization of blots was performed overnight in
5 X SSPE [5 ms'i EDTA, 50 mrvt NaPO4 (pH 7.4), 900 mM NaCI],
5 X Denhardt's solution (0.1% each bovine serum albumin, Ficoll
400 and polyvinylpyrrolidone), 0.1% SDS and 100 xg/ml heat-
denatured calf thymus DNA (Sigma, Castle Hill, NSW, Austra-
lia). Membranes were washed twice with 2 X SSC/0.1% SDS for
10 minutes each at room temperature and once with 0.1 X
SSC/0.1% SDS for 10 minutes at 45°C, air-dried and then exposed
to autoradiographic film. Two dimensional densitometry was
undertaken on the autoradiographs using a computerized densi-
tometer (Molecular Dynamics) and ImageQuant V 3.0 software.
Statistical and data analysis
To account for variability in the amount of PBMC or gut
sample, RNA recovery and efficiency of reverse transcription,
TCR C6 and TCR Ca gene expression were determined as a ratio
of GAPDH gene expression. TCR Vy and V6 subfamily expres-
sion were determined as a ratio of the TCR C6 densitometry score
after each sample had been standardized for TCR C6 gene
expression. Control peripheral blood and control gut group scores
were compared to those of the IgAN group using a Mann-
Whitney U-test. Paired samples were analyzed using the Wilcoxon
rank sum analysis. P < 0.05 was accepted as statistically signifi-
cant.
RESULTS
RNA samples
From the PBMC samples, 20 RNA samples were obtained (10
patient; 10 control) that were suitable for subsequent TCR
analysis. Of the gut biopsies, 11 control and 9 patient RNA
samples were obtained. Those samples with undetectable or
degraded RNA were discarded.
PCR standard curves and standardization of eDNA samples
PCR standard curves were constructed for GAPDH and TCR
C6 using a range of eDNA concentrations obtained from pooled
normal PBMC (Fig. 1). A logistic regression analysis of the curves
showed that for GAPDH r2 = 0.87 and for TCR C6 r2 = 0.92.
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Fig. 1. PCR standard curves for GAPDH (A) and TCR CS (B). Twofold
serial dilutions of pooled normal PBMC cDNA were subjected each in
triplicate to PCR amplification of GAPDH and TCR CS. PCR products
were detected by Southern blotting and hybridization with an internal
oligonucleotide probe. Following densitometry, the signals were plotted as
mean standard error.
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0.5 Fig. 2. TCR Ca and TCR CS gene expression in peripheral blood and gut
biopsies of IgAN patients and controls. The Ca and CS signals were
expressed as a ratio to GAPDH. Results are plotted as mean standard
error. Symbols are: (S) control PBMC; (0) IgAN PBMC; () control gut;
(LII) IgAN gut; P = 0.005; ** = 0.008.
Fig. 3. TCR V7 repertoire expression in peripheral blood and gut
biopsies of IgAN patients and controls. Vy signals were expressed as a
ratio to TCR C& Results are plotted as mean standard error. Symbols
are: (•) control PBMC; (0) IgAN PBMC; (•) control gut; (LI) IgAN gut;
*p = 0.047; = 0.017; *** = 0.021; **** = 0.023.
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Following PCR amplification of GAPDH and TCR CS in the
blood and gut cDNA samples, the concentration of each cDNA
sample was estimated by comparison of the densitometry signal
obtained with the PCR standard curves. cDNA samples were
diluted accordingly and PCR amplification of GAPDH and TCR
CS was repeated to confirm that the signals remained within the
limits of the standard curves.
TCR aj3 and TCR yS expression in controls and IgAN patients
Expression of the af3 TCR and yS TCR (Fig. 2) was determined
in PBMC and gut cDNA samples by PCR amplification using
primers specific for the Ca and CS region of the TCR, respec-
tively. To correct for the amount of tissue available in each
sample, results were expressed as a ratio to GAPDH gene
expression. Ca gene expression was readily detected in the
peripheral blood of IgAN patients and controls, yet there was a
significantly lower level of Ca gene expression in the gut samples
of both patients and controls (patient PBMC vs. gut, P = 0.008;
control PBMC vs. gut, P = 0.005). In contrast, CS gene expression
was relatively high in the PBMC and gut cDNA samples of
patients and controls with no significant differences observed
between the two groups.
TCR Vy and VS repertoire expression in control blood and gut
The usage of Vy and VS genes by yS T cells in the peripheral
blood of controls showed the predominance of Vy2 (Vy9) and
V52 gene segments (Figs. 3 and 4). In addition to Vy2, TCR
transcripts using either Vyl or Vy3 were also readily detected in
the peripheral blood whereas Vy4 expression was low in compar-
ison (Fig. 3). V52 was predominantly expressed by normal periph-
eral yS T cells, although all of the other VS genes were detected
with VS5 being the second most utilized VS gene (Fig. 4). In the
control gut biopsies, TCR y transcripts mainly used Vy3 although
TCR transcripts utilizing Vyl, Vy2 and Vy4 were also detected
(Fig. 3). TCR 6 chain expression in control gut was restricted
largely to V63, and with the exception of V66, all of the other V6
genes were detected but to a lesser degree (Fig. 4). By comparison
of the control blood and gut group scores, we found that the
normal peripheral and gut y6 TCR V region repertoires were
significantly different with respect to TCR y chain expression.
Expression of Vyl was significantly decreased in the gut com-
pared to blood (P = 0.047). Similarly, reduced expression of Vy2
was observed in gut compared to blood (P = 0.017).
TCR Vy and V& repertoire expression in IgAN blood and gut
In IgAN patients, we observed a predominance of Vy3 and
reduced Vy2 usage by y6 T cells in peripheral blood (Fig. 3). Vyl
and Vy4 transcripts were also detected. As with control PBMC,
V62 was the predominant V6 gene utilized by peripheral blood y6
T cells in IgAN and again all of the other V6 genes were detected
with the exception of V64 (Fig. 4). y6 T cells in the gut of IgAN
patients mainly used Vy3 and V61 (Figs. 3 and 4). TCR 6 chain
expression in IgAN gut, however, was remarkably low for all six
V6 genes (Fig. 4). By comparison of the peripheral blood and gut
group scores for 1gAN patients, we found that three V region
genes each had a significantly decreased expression in the gut
compared to blood (Vy2, P = 0.021; V62, P = 0.017; V65, P =
0.049).
Comparison of the 'y& TCR V region expression between IgAN
patients and controls
While the y and 6 TCR V region repertoires did not differ
significantly between the peripheral blood of IgAN patients and
controls, we observed significant differences in Vy and V6 reper-
toire expression between IgAN and control gut biopsies. Vy3 gene
expression was significantly decreased in TgAN gut compared to
control gut (P = 0.023). In addition, there was a significant
decrease in V63 gene expression in IgAN gut compared to control
gut (P = 0.043). Of note, Vy3 and V63 were the predominant V
region genes expressed by y8 T cells in control gut biopsies.
This study has characterized the populations of y6 T cells in gut
mucosa of patients with IgAN. A semiquantitative reverse tran-
scriptase-PCR protocol was used to determine the Vy and V6
repertoire expression by y6 T cells in gut biopsies and peripheral
blood of a group of IgAN patients and controls. Several studies
have previously analyzed the expression of the y6 TCR by TEL
residing in the normal intestinal mucosa using V61 and V62
region specific monoclonal antibodies [25, 30, 311, and by PCR
analysis [31, 32]. In contrast to normal peripheral blood in which
the majority of y6 T cells expressed a receptor encoded by Vy9
and V62 TCR chains [33], those in the gut predominantly
expressed V81 TCR [25, 30—321. We have also shown by semi-
quantitative PCR analysis of TCR transcripts that normal y6 T
cells in the periphery preferentially utilized Vy9 and V62. In
addition, our data demonstrate that the Vyl subfamily is the next
most frequently used Vy subfamily in normal peripheral blood y6
T cells, followed by Vy3 and Vy4. This finding supports that of a
recent report that analyzed the repertoire of Vy genes expressed
by normal peripheral blood y6 T cells using Vy specific monoclo-
nal antibodies [31. Our PCR strategy, represents, therefore, an
accurate measure of y6 TCR expression levels.
In normal gut mucosa, we observed a predominance of V63, as
opposed to V61 [25, 30—32]. Other investigators have also shown,
by PCR analysis, that V63 gene expression was prominent among
mucosal y6 TEL [32, 35]. In previous studies of y6 TCR expression
in normal gut, however, V63 gene expression was not analyzed
due to the absence of a V63 specific monoclonal antibody, which
may explain the discrepancy. By using V region-specific PCR
amplification of TCR transcripts, we were able to identi!' the
other V6 genes used by TCR 6 chain transcripts in normal gut.
Expression of V61, V&2, V64 and V65 genes was observed in
mucosal 6 chain trancripts, but to a lesser degree, whereas
expression of V66 was not detected. Bucht et al [31] also observed
significant expression of V62 and V65 by TCR 6 chain transcripts
in the colon. There was a predominant expression of Vy3 in
normal gut although TCR transcripts utilizing Vyl, Vy2 and Vy4
were detected. The usage of individual Vy genes by yö T cells in
normal duodenal mucosal biopsies has previously been shown to
be biased towards Vyl and Vy3 [35]. Overall, we found significant
differences in the normal peripheral and gut y6 TCR V region
repertoires with respect to TCR y chain expression; expression of
VyT and Vy2 was significantly decreased in the gut compared to
blood. These differences may reflect the different antigens en-
countered by y6 T cells in the periphery and small bowel mucosa.
In the peripheral blood of IgAN patients, Vy3 and V62 were
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DISCUSSION
Human TEL in the gastrointestinal tract most likely play a
crucial role in mucosal immunity [29]. While the majority of these
IEL bear af3 TCR [29], the expression of the y6 TCR by IEL is
also prominent [24, 25]. This study found that TCR c43 and TCR
y6 expression were relatively high in the peripheral blood of TgAN
patients and controls. However, TCR a/3 expression was signifi-
cantly decreased in the gut biopsies of both patients and controls,
whereas TCR y6 expression was high in all gut biopsies with no
significant differences observed between the peripheral and gut
compartments of either group. These findings indicate that a
significant proportion of the T cells in duodenal mucosa, whether
V61 V62 V63 V64 V5 V66 derived from patients with IgAN or control individuals, were y6T
cells.
Fig. 4. TCR V6 repertoire expression in peripheral blood and gut
biopsies of IgAN patients and controls. V6 subfamily signals were
expressed as a ratio to TCR C6. Results are plotted as mean standard
error. Symbols are: (•) control PBMC; (0) IgAN PBMC; (U) control gut;
(0) IgAN gut; * 0.017; ** = 0.043; ***p = 0.049.
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the predominant V region genes utilized by yb T cells. Those in
the gut of IgAN patients mainly used Vy3 and Vbl. By compar-
ison of the peripheral blood and gut group scores for IgAN
patients, we found that Vy2, Vb2, and Vb5 each had a significantly
decreased expression in the gut compared to blood. Furthermore,
while the y and b TCR V region repertoires did not differ
significantly between the peripheral blood of IgAN patients and
controls, y TCR V region expression was significantly different in
IgAN gut compared to control gut biopsies. Vy3 and Vb3 gene
expression were significantly decreased in IgAN gut compared to
control gut, whereas Vy3 and Vb3 were the predominant V region
genes expressed by yfi TCR in control gut biopsies. These findings
indicate that a subpopulation of yb T cells which represent the
majority of yfi T cells in normal gut mucosa are significantly
diminished in the gut of patients with IgAN, suggesting that there
is a "hole" in the mucosal y T cell repertoire in this disease.
We have previously demonstrated in IgAN a reduction in the
proportion of lamina propria IgA plasma cells expressing J chain
mRNA, and by inference, therefore, a reduction in pIgA produc-
tion [121. The production of J chain, which links Ig molecules to
form polymers, is T cell dependent [361. The present demonstra-
tion of a "hole" in the mucosal yb T cell repertoire underpins
these previous findings and lends credence to the view that a
fundamental flaw exists in the mucosal IgA immune system in
IgAN.
Recent experiments indicate that mucosal immunity may be
impaired in yb T cell deficient mice [37]. These mice had
decreased IgA plasma cells in their mucosa, and when adminis-
tered antigen orally were shown to have reduced IgA antibody
production compared to control mice [37]. If human yb T cells
also mediate mucosal IgA responses, it is possible that a "hole" in
the repertoire of yfi T cells, as we observed in the mucosa of IgAN
patients, may lead to fewer IgA plasma cells in the gut, and
impaired IgA mucosal immunity to specific antigen.
In a recent study of immune responses to nasally-administered
cholera toxin, no antigen-specific IgA could be detected in the
nasal washings of patients with IgAN, in contrast to controls [381.
This finding suggests there is indeed a failure of mucosal IgA
immunity in IgAN. Increased production of pIgA in the bone
marrow and increased circulating pIgA levels may then be sec-
ondary to this decreased mucosal production. In this context, it is
of interest to note that, while we did not observe any alteration in
the V region usage of yb T cells in the blood of patients with
IgAN, it has been reported that yfi T cells account for a higher
percentage of circulating CD3 T cells in IgAN, and that this
difference becomes more marked after immunization with tetanus
toxoid [39]. We have also demonstrated increased numbers of yb
T cells infiltrating the renal interstitium in IgAN, but only in those
patients with progressive renal impairment [40], though it is
probable that this finding identifies a role for yb T cells in the
"downstream" events of progressive renal disease rather than the
primary mechanisms underlying mesangial IgA deposition.
yb T cells have also been implicated in the pathogenesis of
coeliac disease, in which gluten-intolerance leads to lesions in the
small intestinal mucosa involving a T cell-mediated immune
response [41, 42]. There is evidence that y T cells are increased
in the small bowel mucosa of patients with coeliac disease [30].
Moreover, Falk et al [35] have shown that the y TCR V region
repertoire in coeliac disease gut differs compared to control gut,
which suggests that y T cells contribute to the mucosal abnor-
mality. Coeliac disease occurs with an increased frequency in
patients with IgAN [43], further supporting an underlying primary
abnormality within the mucosal immune system in IgAN. The
mechanisms leading to a defect in the mucosal yb T cell repertoire
in this disease, however, are speculative. In mice the intestinal
epithelium is an extrathymic location where a highly restricted
subset of y T cells are generated [44]. Although no extrathymic
site for yfi T cell programmed differentiation has yet been
demonstrated in the human, intense speculation on the origins of
IEL is ongoing. The alteration in yfi T cell repertoire in patients
with IgAN may arise from altered processing of yb T cells during
extrathymic ontogeny, or in response to antigen [45] or hormonal
stimuli [46].
In summary, our findings suggest that a defect in the mucosal yfi
T cell repertoire contributes to an abnormality within the mucosal
immune system, and the pathogenesis of IgAN.
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